Michael A. Hollingsworth - Publications

Affiliations: 
University of Nebraska Medical Center, Omaha, NE, United States 
Area:
Biochemistry
Website:
https://www.unmc.edu/eppley/about/faculty/hollingsworth.html

248 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Dailey KM, Small JM, Pullan JE, Winfree S, Vance KE, Orr M, Mallik S, Bayles KW, Hollingsworth MA, Brooks AE. An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. Plos One. 18: e0289183. PMID 37963142 DOI: 10.1371/journal.pone.0289183  0.31
2023 Zheng D, Grandgenett PM, Zhang Q, Baine M, Shi Y, Du Q, Liang X, Wong J, Iqbal S, Preuss K, Kamal A, Yu H, Du H, Hollingsworth MA, Zhang C. radioGWAS: link radiome to genome to discover driver genes with somatic mutations for heterogeneous tumor image phenotype in pancreatic cancer. Medrxiv : the Preprint Server For Health Sciences. PMID 37961101 DOI: 10.1101/2023.11.02.23297995  0.31
2023 Yu SY, Luan Y, Tang S, Abazarikia A, Dong R, Caffrey TC, Hollingsworth MA, Oupicky D, Kim SY. Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2207010. PMID 37083240 DOI: 10.1002/advs.202207010  0.395
2023 Mullen NJ, Shukla SK, Thakur R, Kollala SS, Wang D, Chaika N, LaBreck DA, Mallareddy JR, Price DH, Natarajan A, Mehla K, Sykes DB, Hollingsworth MA, Singh PK. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Biorxiv : the Preprint Server For Biology. PMID 37066260 DOI: 10.1101/2023.04.03.535399  0.439
2022 Mondal P, Patel NS, Bailey K, Aravind S, Cartwright SB, Hollingsworth MA, Lazenby AJ, Carlson MA. Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig. Disease Models & Mechanisms. PMID 36579622 DOI: 10.1242/dmm.049699  0.335
2022 Vance K, Alitinok A, Winfree S, Jensen-Smith H, Swanson BJ, Grandgenett PM, Klute KA, Crichton DJ, Hollingsworth MA. Erratum to: Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors. Cancer Biomarkers : Section a of Disease Markers. PMID 35694915 DOI: 10.3233/CBM-220901  0.599
2022 Rajesh C, Sagar S, Rathinavel AK, Chemparathy DT, Peng XL, Yeh JJ, Hollingsworth MA, Radhakrishnan P. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. International Journal of Molecular Sciences. 23. PMID 35628269 DOI: 10.3390/ijms23105459  0.369
2022 Napoleon JV, Sagar S, Kubica SP, Boghean L, Kour S, King HM, Sonawane YA, Crawford AJ, Gautam N, Kizhake S, Bialk PA, Kmiec E, Mallareddy JR, Patil PP, Rana S, ... ... Hollingsworth MA, et al. Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 119: e2115071119. PMID 35476515 DOI: 10.1073/pnas.2115071119  0.329
2022 Ganguly K, Cox JL, Ghersi D, Grandgenett PM, Hollingsworth MA, Jain M, Kumar S, Batra SK. Mucin 5AC-mediated CD44/ITGB1 clustering mobilizes adipose-derived mesenchymal stem cells to modulate pancreatic cancer stromal heterogeneity. Gastroenterology. PMID 35219699 DOI: 10.1053/j.gastro.2022.02.032  0.318
2022 Vance K, Alitinok A, Winfree S, Jensen-Smith H, Swanson BJ, Grandgenet PM, Klute KA, Crichton DJ, Hollingsworth MA. Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors. Cancer Biomarkers : Section a of Disease Markers. 33: 219-235. PMID 35213363 DOI: 10.3233/CBM-210308  0.612
2022 Saxena S, Molczyk C, Purohit A, Ehrhorn E, Goel P, Prajapati DR, Atri P, Kaur S, Grandgenett PM, Hollingsworth MA, Batra SK, Singh RK. Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. American Journal of Cancer Research. 12: 68-90. PMID 35141005  0.334
2022 Xu PC, You M, Yu SY, Luan Y, Eldani M, Caffrey TC, Grandgenett PM, O'Connell KA, Shukla SK, Kattamuri C, Hollingsworth MA, Singh PK, Thompson TB, Chung S, Kim SY. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Scientific Reports. 12: 1659. PMID 35102236 DOI: 10.1038/s41598-022-05660-7  0.364
2022 King RJ, Shukla SK, He C, Vernucci E, Thakur R, Attri KS, Dasgupta A, Chaika NV, Mulder SE, Abrego J, Murthy D, Gunda V, Pacheco CG, Grandgenett PM, Lazenby AJ, ... Hollingsworth MA, et al. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. PMID 35001076 DOI: 10.1038/s41388-021-02132-6  0.494
2021 Markov SD, Caffrey TC, O' Connell KA, Grunkemeyer JA, Shin S, Hanson R, Patil PP, Shukla SK, Gonzalez D, Crawford AJ, Vance KE, Huang Y, Eberle KC, Radhakrishnan P, Grandgenett PM, ... ... Hollingsworth MA, et al. IgE-based therapeutic combination enhances anti-tumor response in preclinical models of pancreatic cancer. Molecular Cancer Therapeutics. PMID 34625505 DOI: 10.1158/1535-7163.MCT-21-0368  0.542
2021 Bailey KL, Cartwright SB, Patel NS, Remmers N, Lazenby AJ, Hollingsworth MA, Carlson MA. Porcine pancreatic ductal epithelial cells transformed with KRAS and SV40T are tumorigenic. Scientific Reports. 11: 13436. PMID 34183736 DOI: 10.1038/s41598-021-92852-2  0.815
2021 Ahmad IM, Dafferner AJ, O'Connell KA, Mehla K, Britigan BE, Hollingsworth MA, Abdalla MY. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Cancers. 13. PMID 34066839 DOI: 10.3390/cancers13092264  0.353
2021 Swami P, O'Connell KA, Thiyagarajan S, Crawford A, Patil P, Radhakrishnan P, Shin S, Caffrey TC, Grunkemeyer J, Neville T, Vetter SW, Hollingsworth MA, Leclerc E. Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors. Biomolecules. 11. PMID 33915939 DOI: 10.3390/biom11040526  0.316
2021 Saxena S, Prajapati DR, Goel P, Tomar B, Hayashi Y, Atri P, Rachagani S, Grandgenett PM, Hollingsworth MA, Batra SK, Singh RK. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Cancers. 13. PMID 33669221 DOI: 10.3390/cancers13040818  0.348
2021 Sagar S, Leiphrakpam PD, Thomas D, McAndrews KL, Caffrey TC, Swanson BJ, Clausen H, Wandall HH, Hollingsworth MA, Radhakrishnan P. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. Cancer Letters. PMID 33485947 DOI: 10.1016/j.canlet.2021.01.015  0.622
2020 Thomas D, Sagar S, Liu X, Lee HR, Grunkemeyer JA, Grandgenett PM, Caffrey T, O'Connell KA, Swanson B, Marcos-Silva L, Steentoft C, Wandall HH, Maurer HC, Peng XL, Yeh JJ, ... ... Hollingsworth MA, et al. Isoforms of MUC16 Activate Oncogenic Signaling Through EGF Receptors to Enhance the Progression of Pancreatic Cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33359791 DOI: 10.1016/j.ymthe.2020.12.029  0.65
2020 Lenkiewicz E, Malasi S, Hogenson TL, Flores LF, Barham W, Phillips WJ, Roesler AS, Chambers KR, Rajbhandari N, Hayashi A, Grandgenett PM, Hollingsworth MA, Cridebring D, Xiong Y, Lee JH, et al. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. Cancer Research. PMID 32928922 DOI: 10.1158/0008-5472.Can-20-0078  0.345
2020 Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, Mark MT, Steiner L, Benito-Martin A, Lucotti S, Di Giannatale A, ... ... Hollingsworth MA, et al. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell. PMID 32795414 DOI: 10.1016/J.Cell.2020.07.009  0.371
2020 Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, et al. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. The Journal of Clinical Investigation. PMID 32749238 DOI: 10.1172/Jci136760  0.379
2020 Bhattacharya DS, Svechkarev D, Bapat A, Patil P, Hollingsworth MA, Mohs AM. Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44. Acs Biomaterials Science & Engineering. 6: 3585-3598. PMID 32617404 DOI: 10.1021/Acsbiomaterials.0C00115  0.361
2020 Mundry C, Eberle KC, Singh PK, Hollingsworth MA, Mehla K. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Biochimica Et Biophysica Acta. Reviews On Cancer. 188387. PMID 32579889 DOI: 10.1016/J.Bbcan.2020.188387  0.563
2020 Cole KE, Ly QP, Hollingsworth MA, Cox JL, Stromnes IM, Padussis JC, Foster JM, Vargas LM, Talmadge JE. Comparative phenotypes of peripheral blood and spleen cells from cancer patients. International Immunopharmacology. 85: 106655. PMID 32521493 DOI: 10.1016/J.Intimp.2020.106655  0.423
2020 Confeld MI, Mamnoon B, Feng L, Jensen-Smith H, Ray P, Froberg J, Kim J, Hollingsworth MA, Quadir M, Choi Y, Mallik S. Targeting the tumor core: hypoxia-responsive nanoparticles for delivery of chemotherapy to pancreatic tumors. Molecular Pharmaceutics. PMID 32521162 DOI: 10.1021/Acs.Molpharmaceut.0C00247  0.388
2020 Dasgupta A, Shukla SK, Vernucci E, King RJ, Abrego J, Mulder SE, Mullen NJ, Graves G, Buettner K, Thakur R, Murthy D, Attri KS, Wang D, Chaika NV, Pacheco CG, ... ... Hollingsworth MA, et al. SIRT1-NOX4 signaling axis regulates cancer cachexia. The Journal of Experimental Medicine. 217. PMID 32441762 DOI: 10.1084/Jem.20190745  0.522
2020 Olson MT, Wojtynek NE, Talmon GA, Caffrey TC, Radhakrishnan P, Ly QP, Hollingsworth MA, Mohs AM. Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer. Molecular Cancer Therapeutics. PMID 32404409 DOI: 10.1158/1535-7163.Mct-20-0033  0.4
2020 Shukla SK, Markov SD, Attri KS, Vernucci E, King RJ, Dasgupta A, Grandgenett PM, Hollingsworth MA, Singh PK, Yu F, Mehla K. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Cancer Letters. PMID 32344015 DOI: 10.1016/J.Canlet.2020.04.017  0.537
2020 Somerville TD, Biffi G, Daßler-Plenker J, Hur SK, He XY, Vance KE, Miyabayashi K, Xu Y, Maia-Silva D, Klingbeil O, Demerdash OE, Preall JB, Hollingsworth MA, Egeblad M, Tuveson DA, et al. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. Elife. 9. PMID 32329713 DOI: 10.7554/Elife.53381  0.493
2020 Qi B, Crawford AJ, Wojtynek NE, Talmon GA, Hollingsworth MA, Ly QP, Mohs AM. Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging. Theranostics. 10: 3413-3429. PMID 32206099 DOI: 10.7150/Thno.40688  0.389
2020 Shin SC, Thomas D, Radhakrishnan P, Hollingsworth MA. Invasive phenotype induced by low extracellular pH requires mitochondria dependent metabolic flexibility. Biochemical and Biophysical Research Communications. PMID 32081432 DOI: 10.1016/J.Bbrc.2020.02.018  0.368
2020 Yokoyama S, Hamada T, Higashi M, Matsuo K, Maemura K, Kurahara H, Horinouchi M, Hiraki T, Sugimoto T, Akahane T, Yonezawa S, Kornmann M, Batra SK, Hollingsworth MA, Tanimoto A. Predicted Prognosis of Pancreatic Cancer Patients by Machine Learning. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31992588 DOI: 10.1158/1078-0432.Ccr-19-1247  0.423
2020 Somerville TD, Biffi G, Daßler-Plenker J, Hur SK, He X, Vance KE, Miyabayashi K, Xu Y, Maia-Silva D, Klingbeil O, Demerdash OE, Preall JB, Hollingsworth MA, Egeblad M, Tuveson DA, et al. Author response: Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation Elife. DOI: 10.7554/Elife.53381.Sa2  0.415
2020 Mehla K, Caffrey TC, O'Connel KA, Madiyalakan R, Nicodemus CF, Hollingsworth MA. Abstract PR15: A novel NK cell-targeted therapeutic strategy against pancreatic cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr15  0.512
2019 Shakri AR, Zhong TJ, Ma W, Coker C, Kim S, Calluori S, Scholze H, Szabolcs M, Caffrey T, Grandgenett PM, Hollingsworth MA, Tanji K, Kluger MD, Miller G, Biswas AK, et al. Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia. Cancers. 12. PMID 31861290 DOI: 10.3390/Cancers12010003  0.335
2019 Law HC, Lagundžin D, Clement EJ, Qiao F, Wagner ZS, Krieger KL, Costanzo-Garvey D, Caffrey TC, Grem JL, DiMaio DJ, Grandgenett PM, Cook LM, Fisher KW, Yu F, Hollingsworth MA, et al. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31848187 DOI: 10.1158/1078-0432.Ccr-19-1496  0.326
2019 Lin C, Verma V, Lazenby A, Ly QP, Berim LD, Schwarz JK, Madiyalakan M, Nicodemus CF, Hollingsworth MA, Meza JL, Are C, Padussis J, Grem JL. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. PMID 31513018 DOI: 10.1097/Coc.0000000000000599  0.311
2019 Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429. PMID 31467029 DOI: 10.1124/Mol.119.116855  0.383
2019 Liu X, Clemens DL, Grunkemeyer JA, Price JD, O'Connell K, Chapman NM, Storz P, Wen H, Cox JL, Reid WL, Hollingsworth MA, Thayer S. Mucin-1 is required for Coxsackie Virus B3-induced inflammation in pancreatitis. Scientific Reports. 9: 10656. PMID 31337812 DOI: 10.1038/S41598-019-46933-Y  0.398
2019 Caffrey T, Sagar S, Thomas D, Lewallen ME, Hollingsworth MA, Radhakrishnan P. The Glycoprotein Mucin-1 Negatively Regulates GalNAc Transferase 5 Expression in Pancreatic Cancer. Febs Letters. PMID 31283009 DOI: 10.1002/1873-3468.13532  0.795
2019 Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, Spielman B, Da Silva B, Schoepfer C, Wright K, Creighton B, ... ... Hollingsworth MA, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science (New York, N.Y.). 364: 1156-1162. PMID 31221853 DOI: 10.1126/Science.Aaw3145  0.334
2019 Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, ... ... Hollingsworth MA, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. PMID 30996350 DOI: 10.1038/S41586-019-1130-6  0.412
2019 Haney SL, Varney ML, Chhonker YS, Shin S, Mehla K, Crawford AJ, Smith HJ, Smith LM, Murry DJ, Hollingsworth MA, Holstein SA. Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. Oncogene. PMID 30918331 DOI: 10.1038/S41388-019-0794-6  0.377
2019 Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, ... ... Hollingsworth MA, et al. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell. PMID 30686769 DOI: 10.1016/J.Ccell.2018.12.010  0.353
2019 Soni KS, Thomas D, Caffrey T, Mehla K, Lei F, O'Connell KA, Sagar S, Lele SM, Hollingsworth MA, Radhakrishnan P, Bronich TK. Polymeric Nanogel-based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. The Journal of Pharmacology and Experimental Therapeutics. PMID 30683666 DOI: 10.1124/Jpet.118.255372  0.409
2019 Engle D, Tiriac H, Rivera K, Pommier A, Whalen S, Oni T, Alagesan B, Lee E, Yao M, Lucito M, Spielman B, Yu K, Grutzmann R, Aust D, Gimotty P, ... ... Hollingsworth MA, et al. Abstract PR12: The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-Pr12  0.359
2018 Datta K, Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait JK, Guda C, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, Muders MH, Batra SK. Macrophage-derived Neuropilin-2 exhibits novel tumor-promoting functions. Cancer Research. PMID 30111533 DOI: 10.1158/0008-5472.Can-18-0562  0.457
2018 Wang G, Biswas AK, Ma W, Kandpal M, Coker C, Grandgenett PM, Hollingsworth MA, Jain R, Tanji K, Lόpez-Pintado S, Borczuk A, Hebert D, Jenkitkasemwong S, Hojyo S, Davuluri RV, et al. Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nature Medicine. 24: 770-781. PMID 29875463 DOI: 10.1038/S41591-018-0054-2  0.32
2018 Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville T, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, ... ... Hollingsworth MA, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discovery. PMID 29853643 DOI: 10.1158/2159-8290.Cd-18-0349  0.372
2018 Wiest EJ, Smith HJ, Hollingsworth MA. Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum. Biochemical and Biophysical Research Communications. PMID 29752941 DOI: 10.1016/J.Bbrc.2018.05.034  0.363
2018 Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, et al. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 9: 5216-5232. PMID 29435174 DOI: 10.18632/Oncotarget.23749  0.412
2018 Qi B, Crawford AJ, Wojtynek NE, Holmes MB, Souchek JJ, Almeida-Porada G, Ly QP, Cohen SM, Hollingsworth MA, Mohs AM. Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29325740 DOI: 10.1016/J.Nano.2017.12.015  0.38
2018 Engle D, Tiriac H, Pommier A, Schoepfer C, Silva BD, Yao M, Park Y, Hollingsworth MA, Tuveson D. Abstract A27: Exploring the role of glycosylation in pancreatic disease Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-A27  0.324
2018 Freeman SS, Lin Z, Ha G, Leshchiner I, Rhoades J, Livitz D, Rosebrock D, Reed SC, Gydush G, Lo C, Rotem D, Choudhury AD, Stover DG, Parsons HA, Boehm JS, ... ... Hollingsworth MA, et al. Abstract LB-225: Liquid biopsies identify trunk mutations and reflect multiple tumors in a patient Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-225  0.4
2018 Qi B, Crawford A, Cohen S, Hollingsworth M, Mohs AM. Abstract 4102: Surgical imaging of pancreatic cancer using near infrared fluorescent hyaluronic acid nanomaterials Cancer Research. 78: 4102-4102. DOI: 10.1158/1538-7445.Am2018-4102  0.423
2017 Mehla K, Tremayne J, Grunkemeyer JA, O'Connell KA, Steele MM, Caffrey TC, Zhu X, Yu F, Singh PK, Schultes BC, Madiyalakan R, Nicodemus CF, Hollingsworth MA. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunology, Immunotherapy : Cii. PMID 29204701 DOI: 10.1007/S00262-017-2095-7  0.819
2017 Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, ... ... Hollingsworth MA, et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 32: 392. PMID 28898700 DOI: 10.1016/J.Ccell.2017.08.008  0.452
2017 Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, ... ... Hollingsworth MA, et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. PMID 28757253 DOI: 10.1016/J.Cell.2017.07.007  0.384
2017 Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, ... ... Hollingsworth MA, et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 32: 71-87.e7. PMID 28697344 DOI: 10.1016/J.Ccell.2017.06.004  0.525
2017 Yokoyama S, Higashi M, Tsutsumida H, Wakimoto J, Hamada T, Wiest E, Matsuo K, Kitazono I, Goto Y, Guo X, Hamada T, Yamada S, Hiraki T, Yonezawa S, Batra SK, ... Hollingsworth MA, et al. TET1-mediated DNA hypomethylation regulates the expression of MUC4 in lung cancer. Genes & Cancer. 8: 517-527. PMID 28680536 DOI: 10.18632/Genesandcancer.139  0.341
2017 Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, Oupicky D. Emerging Roles of the CXCL12/CXCR4 Axis in Pancreatic Cancer Progression and Therapy. Pharmacology & Therapeutics. PMID 28549596 DOI: 10.1016/J.Pharmthera.2017.05.012  0.488
2017 Mehla K, Grunkemeyer JA, O'Connell KA, Steele MM, Caffrey T, Madiyalakan R, Nicodemus CF, Hollingsworth MA. Abstract A30: AR20.5-based novel immunotherapy for pancreatic cancer Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-A30  0.526
2017 Remmers NA, Cox JL, Grandgenett PM, Grunkemeyer JA, Rund LA, Schook LB, Hollingsworth MA, Carlson MA. Abstract 813: Development of a porcine model for pancreatic cancer Cancer Research. 77: 813-813. DOI: 10.1158/1538-7445.Am2017-813  0.483
2016 Kaur S, Smith LM, Patel A, Menning M, Watley DC, Malik SS, Krishn SR, Mallya K, Aithal A, Sasson AR, Johansson SL, Jain M, Singh S, Guha S, Are C, ... ... Hollingsworth MA, et al. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. The American Journal of Gastroenterology. PMID 27845339 DOI: 10.1038/Ajg.2016.482  0.339
2016 Clausen TM, Pereira MA, Al Nakouzi N, Oo HZ, Agerbæk MO, Lee S, Orum-Madsen MS, Kristensen AR, El-Naggar A, Grandgenett PM, Grem JL, Hollingsworth MA, Holst PJ, Theander TG, Sorensen PH, et al. Oncofetal Chondroitin Sulfate Glycosaminoglycans are Key Players in Integrin Signaling and Tumor Cell Motility. Molecular Cancer Research : McR. PMID 27655130 DOI: 10.1158/1541-7786.Mcr-16-0103  0.493
2016 Sousa AM, Rei M, Freitas R, Ricardo S, Caffrey T, David L, Almeida R, Hollingsworth MA, Santos-Silva F. Effect of MUC1/β-catenin interaction on the tumorigenic capacity of pancreatic CD133(+) cells. Oncology Letters. 12: 1811-1817. PMID 27602113 DOI: 10.3892/Ol.2016.4888  0.403
2016 Liu J, Luo Z, Zhang L, Wang L, Nie Q, Wang ZF, Huang Z, Hu X, Gong L, Arrigo AP, Tang X, Xiang JW, Liu F, Deng M, Ji W, ... ... Hollingsworth MA, et al. The small heat shock protein αA-crystallin negatively regulates pancreatic tumorigenesis. Oncotarget. PMID 27588467 DOI: 10.18632/Oncotarget.11668  0.477
2016 Sousa AM, Grandgenett PM, David L, Almeida R, Hollingsworth MA, Santos-Silva F. Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. PMID 27538373 DOI: 10.1111/Apm.12587  0.405
2016 Yokoyama S, Higashi M, Kitamoto S, Oeldorf M, Knippschild U, Kornmann M, Maemura K, Kurahara H, Wiest E, Hamada T, Kitazono I, Goto Y, Tasaki T, Hiraki T, Hatanaka K, ... ... Hollingsworth MA, et al. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas. Oncotarget. PMID 27283771 DOI: 10.18632/Oncotarget.9924  0.352
2016 Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp JL, Kritzik M, Sicklick JK, Sander M, Grandgenett PM, Hollingsworth MA, et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature. PMID 27281208 DOI: 10.1038/Nature17988  0.437
2016 Hanson RL, Brown RB, Steele MM, Grandgenett PM, Grunkemeyer JA, Hollingsworth MA. Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis. Oncotarget. PMID 27220889 DOI: 10.18632/Oncotarget.9557  0.449
2016 Wuebben EL, Wilder PJ, Cox JL, Grunkemeyer JA, Caffrey T, Hollingsworth MA, Rizzino A. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. Oncotarget. PMID 27145457 DOI: 10.18632/Oncotarget.8994  0.386
2016 Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer D, Hollingsworth MA, Anderson KS. Proteomic Mapping of p53 Immunogenicity in Pancreatic, Ovarian, and Breast Cancers. Proteomics. Clinical Applications. PMID 27121307 DOI: 10.1002/Prca.201500096  0.385
2016 Krishn SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, Lo WC, Fan WL, Manne U, Batra SK. Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Letters. PMID 26898938 DOI: 10.1016/J.Canlet.2016.02.016  0.367
2016 Steele MM, Fogler WE, Magnani JL, Hollingsworth MA. Abstract 902: A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) delays pancreatic tumor metastasis and significantly alters the pancreatic tumor microenvironment Cancer Research. 76: 902-902. DOI: 10.1158/1538-7445.Am2016-902  0.491
2016 Torphy R, Rashid N, Moffitt R, Hollingsworth MA, Yeh JJ. Activated Stroma Differences at Metastatic Sites in Pancreatic Cancer Journal of the American College of Surgeons. 223: e132. DOI: 10.1016/J.Jamcollsurg.2016.08.340  0.371
2015 Fink DM, Steele MM, Hollingsworth MA. The lymphatic system and pancreatic cancer. Cancer Letters. PMID 26742462 DOI: 10.1016/J.Canlet.2015.11.048  0.422
2015 Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, ... ... Hollingsworth MA, et al. Tumour exosome integrins determine organotropic metastasis. Nature. PMID 26524530 DOI: 10.1038/Nature15756  0.354
2015 Kelly KA, Hollingsworth MA, Brand RE, Liu CH, Singh VK, Srivastava S, Wasan AD, Yadav D, Andersen DK. Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop. Pancreas. 44: 1185-94. PMID 26465948 DOI: 10.1097/Mpa.0000000000000552  0.341
2015 Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, ... ... Hollingsworth MA, et al. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. Plos One. 10: e0139049. PMID 26431551 DOI: 10.1371/Journal.Pone.0139049  0.337
2015 Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, ... ... Hollingsworth MA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics. 47: 1168-78. PMID 26343385 DOI: 10.1038/Ng.3398  0.326
2015 Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, ... ... Hollingsworth MA, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nature Cell Biology. 17: 816-26. PMID 25985394 DOI: 10.1038/Ncb3169  0.34
2015 Pandey P, Rachagani S, Das S, Seshacharyulu P, Sheinin Y, Naslavsky N, Pan Z, Smith BL, Peters HL, Radhakrishnan P, McKenna NR, Giridharan SS, Haridas D, Kaur S, Hollingsworth MA, et al. Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis. Oncotarget. 6: 2064-75. PMID 25576918 DOI: 10.18632/Oncotarget.2990  0.494
2015 Torphy RJ, Volmar KE, Naim R, Cader SR, Johansen JS, Hollingsworth MA, Collisson EA, Yeh JJ. Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma. Journal of Clinical Oncology. 33: 4021-4021. DOI: 10.1200/JCO.2015.33.15_SUPPL.4021  0.301
2015 Soni KS, Hollingsworth MA, Radhakrishnan P, Bronich TK. Abstract 5517: Polymeric nanogel-based treatment regimen for enhanced efficacy and sequential administration of synergistic drug combination in pancreatic cancer Cancer Research. 75: 5517-5517. DOI: 10.1158/1538-7445.Am2015-5517  0.313
2015 Fink DM, Connor AL, Kelley PM, Tempero RM, Hollingsworth MA. Abstract 5220: Inflamed and wound recovered tumor microenvironment contributions to lymphatic-mediated metastasis Cancer Research. 75: 5220-5220. DOI: 10.1158/1538-7445.Am2015-5220  0.436
2015 Hanson RL, Hollingsworth MA. Abstract 508: Identification of FRA-1 as a potential driver of pro-invasive properties in pancreatic cancer in conjunction with MUC1 Cancer Research. 75: 508-508. DOI: 10.1158/1538-7445.Am2015-508  0.508
2015 Steele MM, Fogler WE, Magnani JL, Hollingsworth MA. Abstract 425: A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) prevents pancreatic tumor metastasis and improves chemotherapy Cancer Research. 75: 425-425. DOI: 10.1158/1538-7445.Am2015-425  0.485
2014 Liu X, Huang H, Remmers N, Hollingsworth MA. Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis. Tissue Barriers. 2: e969112. PMID 25610757 DOI: 10.4161/21688362.2014.969112  0.824
2014 Zhao Q, Piyush T, Chen C, Hollingsworth MA, Hilkens J, Rhodes JM, Yu LG. MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis. Cell Death & Disease. 5: e1438. PMID 25275599 DOI: 10.1038/Cddis.2014.421  0.398
2014 Mirus JE, Zhang Y, Hollingsworth MA, Solan JL, Lampe PD, Hingorani SR. Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease. Molecular & Cellular Proteomics : McP. 13: 3484-96. PMID 25225358 DOI: 10.1074/Mcp.M113.036517  0.376
2014 Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, Vakhrushev SY, Olsen JV, Hansen L, Bennett EP, Woetmann A, Yin G, Chen L, Song H, Bak M, ... ... Hollingsworth MA, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proceedings of the National Academy of Sciences of the United States of America. 111: E4066-75. PMID 25118277 DOI: 10.1073/Pnas.1406619111  0.353
2014 Liu X, Caffrey TC, Steele MM, Mohr A, Singh PK, Radhakrishnan P, Kelly DL, Wen Y, Hollingsworth MA. MUC1 regulates cyclin D1 gene expression through p120 catenin and β-catenin. Oncogenesis. 3: e107. PMID 24979278 DOI: 10.1038/oncsis.2014.19  0.613
2014 Cox JL, Wilder PJ, Wuebben EL, Ouellette MM, Hollingsworth MA, Rizzino A. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma. Cancer Biology & Therapy. 15: 1042-52. PMID 24841553 DOI: 10.4161/Cbt.29182  0.465
2014 Thege FI, Lannin TB, Saha TN, Tsai S, Kochman ML, Hollingsworth MA, Rhim AD, Kirby BJ. Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. Lab On a Chip. 14: 1775-84. PMID 24681997 DOI: 10.1039/C4Lc00041B  0.401
2014 Liu X, Yi C, Wen Y, Radhakrishnan P, Tremayne JR, Dao T, Johnson KR, Hollingsworth MA. Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. Cancer Research. 74: 1609-20. PMID 24371222 DOI: 10.1158/0008-5472.Can-13-2444  0.795
2014 Kaur S, Sharma N, Krishn SR, Lakshmanan I, Rachagani S, Baine MJ, Smith LM, Lele SM, Sasson AR, Guha S, Mallya K, Anderson JM, Hollingsworth MA, Batra SK. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 688-700. PMID 24240113 DOI: 10.1158/1078-0432.Ccr-13-2174  0.399
2014 Katchman BA, Alam R, Wallstrom G, LaBaer J, Hollingsworth MA, Cramer DW, Anderson KS. Abstract 881: Identification of autoantibody biomarkers to wild-type and mutant p53 in pancreatic and ovarian cancer Cancer Research. 74: 881-881. DOI: 10.1158/1538-7445.Am2014-881  0.362
2014 Fink DM, Connor AL, Kelley PM, Tempero RM, Hollingsworth MA. Abstract 4942: Metastatic tumor migration in lymphatic vessels revealed by real-time intravital imaging Cancer Research. 74: 4942-4942. DOI: 10.1158/1538-7445.Am2014-4942  0.443
2014 Steele MM, Radhakrishnan P, Magnani JL, Hollingsworth MA. Abstract 4503: A small molecule glycomimetic antagonist of E-selectin (GMI-1271) prevents pancreatic tumor metastasis and offers a novel treatment for improved efficacy of chemotherapy Cancer Research. 74: 4503-4503. DOI: 10.1158/1538-7445.Am2014-4503  0.425
2013 Radhakrishnan P, Mohr AM, Grandgenett PM, Steele MM, Batra SK, Hollingsworth MA. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. Plos One. 8: e73356. PMID 24204560 DOI: 10.1371/Journal.Pone.0073356  0.39
2013 Mohr AM, Bailey JM, Lewallen ME, Liu X, Radhakrishnan P, Yu F, Tapprich W, Hollingsworth MA. MUC1 regulates expression of multiple microRNAs involved in pancreatic tumor progression, including the miR-200c/141 cluster. Plos One. 8: e73306. PMID 24143167 DOI: 10.1371/Journal.Pone.0073306  0.764
2013 Radhakrishnan P, Grandgenett PM, Mohr AM, Bunt SK, Yu F, Chowdhury S, Hollingsworth MA. Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. International Journal of Cancer. Journal International Du Cancer. 133: 2824-33. PMID 23754791 DOI: 10.1002/Ijc.28322  0.516
2013 Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Research. 73: 1821-30. PMID 23467612 DOI: 10.1158/0008-5472.Can-12-2067  0.469
2013 Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH, Mandel U, Clausen H, Yu F, Hollingsworth MA. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1981-93. PMID 23446997 DOI: 10.1158/1078-0432.Ccr-12-2662  0.81
2013 Bunt SK, Mohr AM, Bailey JM, Grandgenett PM, Hollingsworth MA. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunology, Immunotherapy : Cii. 62: 225-36. PMID 22864396 DOI: 10.1007/S00262-012-1324-3  0.48
2013 Purohit V, Chaika NV, Gebregiworgis T, Radhakrishnan P, Zhang B, Mehla K, Yu F, Johnson KR, Powers R, Hollingsworth MA, Singh PK. Abstract 5391: MUC1 and HIF-1α signaling interactions modulate glucose flux in pancreatic cancer. Cancer Research. 73: 5391-5391. DOI: 10.1158/1538-7445.Am2013-5391  0.519
2012 Dey P, Rachagani S, Chakraborty S, Singh PK, Zhao X, Gurumurthy CB, Anderson JM, Lele S, Hollingsworth MA, Band V, Batra SK. Overexpression of ecdysoneless in pancreatic cancer and its role in oncogenesis by regulating glycolysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6188-98. PMID 22977192 DOI: 10.1158/1078-0432.Ccr-12-1789  0.558
2012 Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, Zhang B, Mehla K, Brown RB, Caffrey T, Yu F, Johnson KR, Powers R, Hollingsworth MA, Singh PK. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 13787-92. PMID 22869720 DOI: 10.1073/Pnas.1203339109  0.806
2012 Peters HL, Tuli A, Wang X, Liu C, Pan Z, Ouellette MM, Hollingsworth MA, Macdonald RG, Solheim JC. Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells. International Journal of Oncology. 41: 1464-74. PMID 22797723 DOI: 10.3892/Ijo.2012.1553  0.439
2012 Mutolo MJ, Morris KJ, Leir SH, Caffrey TC, Lewandowska MA, Hollingsworth MA, Harris A. Tumor suppression by collagen XV is independent of the restin domain. Matrix Biology : Journal of the International Society For Matrix Biology. 31: 285-9. PMID 22531369 DOI: 10.1016/J.Matbio.2012.03.003  0.367
2012 Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, Yeh JJ, Johnson KR, Hollingsworth MA, Singh PK. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. Plos One. 7: e32996. PMID 22412968 DOI: 10.1371/Journal.Pone.0032996  0.57
2012 Remmers N, Bailey JM, Mohr AM, Hollingsworth MA. MOlecular Pathology Of Early Pancreatic Cancer Translational Pathology of Early Cancer. 421-440. DOI: 10.3233/978-1-61499-024-6-421  0.794
2012 Radhakrishnan P, Grunkemeyer JA, Clausen H, Hollingsworth MA. Abstract A69: TruncatedO-glycans enhance tumorigenicity of pancreatic tumors. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A69  0.53
2012 Lin W, Rajbhandari N, Liu C, Sakamoto K, Batra S, Opavsky R, Felsher D, Hollingsworth M, Hebrok M, Rui H, Wagner K. Abstract LB-429: Dormant cancer cells contribute to residual disease in a mouse model for reversible pancreatic cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-429  0.45
2012 Purohit V, Chaika NV, Gebregiworgis TG, Powers R, Johnson KR, Hollingsworth MA, Singh PK. Abstract 5152: Targeting HIF1α-mediated metabolic alterations in pancreatic cancer Cancer Research. 72: 5152-5152. DOI: 10.1158/1538-7445.Am2012-5152  0.551
2012 Fink DM, Tremayne J, Bunt SK, Hollingsworth MA. Abstract 1575: A dual immunostimulatory strategy for pancreatic cancer treatment: MUC1 cytoplasmic tail peptide therapeutic vaccine with adjuvant TLR3 agonist poly(I:C12U) Cancer Research. 72: 1575-1575. DOI: 10.1158/1538-7445.Am2012-1575  0.417
2012 Bunt SK, Mohr AM, Bailey JM, Grandgenett PM, Hollingsworth MA. Abstract 1554: Rosiglitazone and Gemcitabine combination therapy reduces immune suppression and modulates T cell populations in pancreatic cancer Cancer Research. 72: 1554-1554. DOI: 10.1158/1538-7445.Am2012-1554  0.484
2012 Shroff RT, Morris J, Nogueras-Gonzalez GM, Anderson JM, Hollingsworth MA, Abbruzzese JL, Wang HM. Abstract 1493: Analysis of fibrosis and stromal components in metastatic pancreatic cancer (PC) autopsy specimens Cancer Research. 72: 1493-1493. DOI: 10.1158/1538-7445.Am2012-1493  0.387
2012 Grandgenett PM, Bunt SK, Mohr AM, Radhakrishnan P, Hamada T, Hollingsworth MA. Abstract 1304: Specific MUC1 isoforms function to regulate gene expression and tumor growth in pancreatic cancer Cancer Research. 72: 1304-1304. DOI: 10.1158/1538-7445.Am2012-1304  0.495
2011 Singh PK, Mehla K, Hollingsworth MA, Johnson KR. Regulation of Aerobic Glycolysis by microRNAs in Cancer. Molecular and Cellular Pharmacology. 3: 125-134. PMID 22792411 DOI: 10.4255/Mcpharmacol.11.17  0.561
2011 Costa NR, Paulo P, Caffrey T, Hollingsworth MA, Santos-Silva F. Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. Plos One. 6: e26970. PMID 22073229 DOI: 10.1371/Journal.Pone.0026970  0.311
2011 Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM, Anderson JM, Wittel UA, Hollingsworth MA, Batra SK. Pathobiological implications of MUC16 expression in pancreatic cancer. Plos One. 6: e26839. PMID 22066010 DOI: 10.1371/Journal.Pone.0026839  0.427
2011 Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, Ouellette M, Hollingsworth MA. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6140-50. PMID 21825040 DOI: 10.1158/1078-0432.Ccr-10-2288  0.769
2011 Taniuchi K, Nishimori I, Hollingsworth MA. The N-terminal domain of G3BP enhances cell motility and invasion by posttranscriptional regulation of BART. Molecular Cancer Research : McR. 9: 856-66. PMID 21665939 DOI: 10.1158/1541-7786.Mcr-10-0574  0.387
2011 Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, Saibara T, Hollingsworth MA. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene. 30: 4843-54. PMID 21625220 DOI: 10.1038/Onc.2011.194  0.419
2011 Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Research : Bcr. 13: R25. PMID 21385452 DOI: 10.1186/Bcr2841  0.336
2011 Taniuchi K, Nishimori I, Hollingsworth MA. Intracellular CD24 inhibits cell invasion by posttranscriptional regulation of BART through interaction with G3BP. Cancer Research. 71: 895-905. PMID 21266361 DOI: 10.1158/0008-5472.Can-10-2743  0.366
2011 Bryant VC, Radhakrishnan P, Hollingsworth MA, Natarajan A. Abstract LB-206: A novel scaffold that targets the IKK complex Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-206  0.398
2011 Singh PK, Purohit V, Chaika N, Johnson KR, Hollingsworth MA. Abstract 991: Regulation of glucose metabolism by HIF in pancreatic cancer Cellular and Molecular Biology. 71: 991-991. DOI: 10.1158/1538-7445.Am2011-991  0.32
2011 Remmers NA, Anderson JM, Singh PK, Hollingsworth MA. Abstract 895: Glycopeptides in pancreatic adenocarcinoma Cancer Research. 71: 895-895. DOI: 10.1158/1538-7445.Am2011-895  0.456
2011 Liu X, Yi C, Hollingsworth MA. Abstract 4010: Significant roles of p120 catenin and MUC1 in promoting invasive behavior of pancreatic cancer cells Cancer Research. 71: 4010-4010. DOI: 10.1158/1538-7445.Am2011-4010  0.682
2011 Bailey JM, Rasheed Z, Matsui W, Maitra A, Hollingsworth MA, Leach SD. Abstract 2449: Pancreatic cancer tumor initiating cells are marked by the presence of a primary cilium Cancer Research. 71: 2449-2449. DOI: 10.1158/1538-7445.Am2011-2449  0.517
2011 Lin W, Zhang Q, Opavsky R, DiMaio DJ, Felsher DW, Batra SK, Hollingsworth MA, Wagner K. Abstract 2384: A novel mouse model for the study of c-MYC during initiation and progression of pancreatic ductal adenocarcinoma Cancer Research. 71: 2384-2384. DOI: 10.1158/1538-7445.Am2011-2384  0.462
2010 Remmers N, Bailey JM, Mohr AM, Hollingsworth MA. Molecular pathology of early pancreatic cancer. Cancer Biomarkers : Section a of Disease Markers. 9: 421-40. PMID 22112488 DOI: 10.3233/Cbm-2011-0168  0.793
2010 Behrens ME, Grandgenett PM, Bailey JM, Singh PK, Yi CH, Yu F, Hollingsworth MA. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene. 29: 5667-77. PMID 20697347 DOI: 10.1038/Onc.2010.327  0.657
2010 Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, ... Hollingsworth MA, et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. Plos Medicine. 7: e1000307. PMID 20644708 DOI: 10.1371/Journal.Pmed.1000307  0.303
2010 Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Research. 70: 1306-13. PMID 20124478 DOI: 10.1158/0008-5472.Can-09-2893  0.355
2010 Hollingsworth MA. Abstract CN09-04: Molecular approaches to early detection of pancreatic cancer Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-Cn09-04  0.349
2010 Bunt SK, Hollingsworth MA. Abstract 5391: Rosiglitazone and Gemcitabine combination therapy limits tumor progression and prolongs survival in pancreatic adenocarcinoma Cancer Research. 70: 5391-5391. DOI: 10.1158/1538-7445.Am10-5391  0.473
2010 Behrens M, Grandgenett P, Bailey J, Singh P, Yi C, Hollingsworth M. Abstract 5077: Signaling through the cytoplasmic tail of MUC1 directly activates transcription of the metastasis promoting growth factor CTGF in pancreatic adenocarcinoma Cancer Research. 70: 5077-5077. DOI: 10.1158/1538-7445.Am10-5077  0.698
2010 Remmers N, Rothermund-Franklin C, Caffrey T, Hollingsworth MA. Abstract 2720: Glycosylation of Mucins Expressed in Pancreatic Adenocarcinoma Cancer Research. 70: 2720-2720. DOI: 10.1158/1538-7445.Am10-2720  0.806
2010 Rei MM, Freitas R, Sousa A, Caffrey TC, Hollingsworth MA, Silva FS. T1724 Characterization of MUC1 Signaling Pathways in Pancreatic Cancer Stem Cells Gastroenterology. 138: S-565. DOI: 10.1016/S0016-5085(10)62602-9  0.368
2009 Bailey JM, Creamer BA, Hollingsworth MA. What a fish can learn from a mouse: principles and strategies for modeling human cancer in mice. Zebrafish. 6: 329-37. PMID 20047466 DOI: 10.1089/Zeb.2009.0626  0.359
2009 Moniaux N, Nemos C, Deb S, Zhu B, Dornreiter I, Hollingsworth MA, Batra SK. The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. Plos One. 4: e7077. PMID 19771162 DOI: 10.1371/Journal.Pone.0007077  0.333
2009 Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene. 28: 3513-25. PMID 19633682 DOI: 10.1038/Onc.2009.220  0.516
2009 Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Molecular & Cellular Proteomics : McP. 8: 1697-707. PMID 19377061 DOI: 10.1074/Mcp.M900135-Mcp200  0.362
2009 Wilder PJ, Chakravarthy H, Hollingsworth MA, Rizzino A. Comparison of ras-responsive gene enhancers in pancreatic tumor cells that express either wild-type or mutant K-ras. Biochemical and Biophysical Research Communications. 381: 706-11. PMID 19254697 DOI: 10.1016/J.Bbrc.2009.02.126  0.384
2008 Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5995-6004. PMID 18829478 DOI: 10.1158/1078-0432.Ccr-08-0291  0.774
2008 Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. The Journal of Biological Chemistry. 283: 26985-95. PMID 18625714 DOI: 10.1074/Jbc.M805036200  0.689
2008 Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, Brand RE, Hollingsworth MA, Jain M, Batra SK. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. British Journal of Cancer. 98: 1540-7. PMID 18392050 DOI: 10.1038/Sj.Bjc.6604329  0.428
2008 Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Research. 68: 2065-70. PMID 18381409 DOI: 10.1158/0008-5472.Can-07-6041  0.56
2008 Shintani Y, Fukumoto Y, Chaika N, Grandgenett PM, Hollingsworth MA, Wheelock MJ, Johnson KR. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. International Journal of Cancer. Journal International Du Cancer. 122: 71-7. PMID 17721921 DOI: 10.1002/Ijc.23027  0.443
2008 Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells (Cancer Research (April 1, 2008) 68(2065-2070)) Cancer Research. 68: 3549. DOI: 10.1158/0008-5472.Can-68-9-Cor3  0.453
2008 Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion (Cancer Research (2007) 67, (10222-10229)) Cancer Research. 68: 338. DOI: 10.1158/0008-5472.Can-68-1-Cor  0.787
2007 Harris A, Harris H, Hollingsworth MA. Complete suppression of tumor formation by high levels of basement membrane collagen. Molecular Cancer Research : McR. 5: 1241-5. PMID 18171981 DOI: 10.1158/1541-7786.Mcr-07-0200  0.383
2007 Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Research. 67: 10222-9. PMID 17974963 DOI: 10.1158/0008-5472.Can-06-2483  0.819
2007 Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. Journal of Cellular Biochemistry. 102: 829-39. PMID 17914743 DOI: 10.1002/Jcb.21509  0.561
2007 Ashour AE, Turnquist HR, Burns N, Wang X, Lin X, Tremayne J, Hollingsworth MA, Blonder JM, Rosenthal GJ, Talmadge JE, Solheim JC. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. Cancer Biotherapy & Radiopharmaceuticals. 22: 235-8. PMID 17600470 DOI: 10.1089/Cbr.2007.336  0.811
2007 Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, Gendler SJ, Hollingsworth MA. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Research. 67: 5201-10. PMID 17545600 DOI: 10.1158/0008-5472.Can-06-4647  0.765
2007 Yi CH, Smith DJ, West WW, Hollingsworth MA. Loss of fibulin-2 expression is associated with breast cancer progression. The American Journal of Pathology. 170: 1535-45. PMID 17456760 DOI: 10.2353/Ajpath.2007.060478  0.614
2007 Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. International Journal of Oncology. 30: 631-9. PMID 17273764 DOI: 10.3892/Ijo.30.3.631  0.472
2007 Wandall HH, Irazoqui F, Tarp MA, Bennett EP, Mandel U, Takeuchi H, Kato K, Irimura T, Suryanarayanan G, Hollingsworth MA, Clausen H. The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. Glycobiology. 17: 374-87. PMID 17215257 DOI: 10.1093/Glycob/Cwl082  0.767
2007 Singh AP, Chauhan SC, Andrianifahanana M, Moniaux N, Meza JL, Copin MC, van Seuningen I, Hollingsworth MA, Aubert JP, Batra SK. MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene. 26: 30-41. PMID 16799633 DOI: 10.1038/Sj.Onc.1209764  0.422
2007 Yue T, Chen S, Goldstein I, Hollingsworth MA, Simeone D, Brand RE, Haab BB. PROFILING GLYCAN STRUCTURES ON MUCINS IN THE SERA OF PANCREATIC CANCER PATIENTS USING ANTIBODY ARRAYS Pancreas. 35: 437-438. DOI: 10.1097/01.Mpa.0000297820.29441.D1  0.341
2006 Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Research. 66: 11745-53. PMID 17178870 DOI: 10.1158/0008-5472.Can-06-2322  0.425
2006 Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends in Cell Biology. 16: 467-76. PMID 16904320 DOI: 10.1016/J.Tcb.2006.07.006  0.448
2006 Tsutsumida H, Swanson BJ, Singh PK, Caffrey TC, Kitajima S, Goto M, Yonezawa S, Hollingsworth MA. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2976-87. PMID 16707592 DOI: 10.1158/1078-0432.Ccr-05-1197  0.724
2006 Moniaux N, Nemos C, Schmied BM, Chauhan SC, Deb S, Morikane K, Choudhury A, Vanlith M, Sutherlin M, Sikela JM, Hollingsworth MA, Batra SK. The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene. 25: 3247-57. PMID 16491129 DOI: 10.1038/Sj.Onc.1209353  0.772
2006 Sørensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology. 16: 96-107. PMID 16207894 DOI: 10.1093/Glycob/Cwj044  0.409
2005 Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 8: 421-32. PMID 16286249 DOI: 10.1016/J.Ccr.2005.10.004  0.393
2005 Lee KM, Yasuda H, Hollingsworth MA, Ouellette MM. Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Laboratory Investigation; a Journal of Technical Methods and Pathology. 85: 1003-12. PMID 15924149 DOI: 10.1038/Labinvest.3700298  0.44
2005 Shiraga T, Winpenny JP, Carter EJ, McCarthy VA, Hollingsworth MA, Harris A. MZF-1 and DbpA interact with DNase I hypersensitive sites that correlate with expression of the human MUC1 mucin gene. Experimental Cell Research. 308: 41-52. PMID 15893750 DOI: 10.1016/J.Yexcr.2005.04.008  0.35
2005 von Mensdorff-Pouilly S, Kinarsky L, Engelmann K, Baldus SE, Verheijen RH, Hollingsworth MA, Pisarev V, Sherman S, Hanisch FG. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology. 15: 735-46. PMID 15814824 DOI: 10.1093/Glycob/Cwi058  0.345
2005 Parry S, Sutton-Smith M, Heal P, Leir SH, Palmai-Pallag T, Morris HR, Hollingsworth MA, Dell A, Harris A. Evaluation of MUC6 mucin tandem repeats. Biochimica Et Biophysica Acta. 1722: 77-83. PMID 15716126 DOI: 10.1016/J.Bbagen.2004.11.010  0.333
2005 Pisarev VM, Kinarsky L, Caffrey T, Hanisch FG, Sanderson S, Hollingsworth MA, Sherman S. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1. International Immunopharmacology. 5: 315-30. PMID 15652762 DOI: 10.1016/J.Intimp.2004.10.004  0.387
2005 Lawson T, Ouellette M, Kolar C, Hollingsworth M. Culture and immortalization of pancreatic ductal epithelial cells Methods in Molecular Medicine. 103: 113-122. PMID 15542901 DOI: 10.1385/1-59259-780-7:113  0.314
2004 Kohlgraf KG, Gawron AJ, Higashi M, VanLith ML, Shen X, Caffrey TC, Anderson JM, Hollingsworth MA. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunology, Immunotherapy : Cii. 53: 1068-84. PMID 15696607 DOI: 10.1007/S00262-004-0557-1  0.802
2004 Turnquist HR, Kohlgraf KG, McIlhaney MM, Mosley RL, Hollingsworth MA, Solheim JC. Tapasin decreases immune responsiveness to a model tumor antigen. Journal of Clinical Immunology. 24: 462-70. PMID 15163903 DOI: 10.1023/B:Joci.0000029118.51587.D9  0.824
2004 Shibahara H, Tamada S, Goto M, Oda K, Nagino M, Nagasaka T, Batra SK, Hollingsworth MA, Imai K, Nimura Y, Yonezawa S. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. The American Journal of Surgical Pathology. 28: 327-38. PMID 15104295 DOI: 10.1097/00000478-200403000-00005  0.38
2004 Choudhury A, Moniaux N, Ulrich AB, Schmied BM, Standop J, Pour PM, Gendler SJ, Hollingsworth MA, Aubert JP, Batra SK. MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFbeta2. British Journal of Cancer. 90: 657-64. PMID 14760381 DOI: 10.1038/Sj.Bjc.6601604  0.399
2004 Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (Baltimore, Md.). 39: 220-9. PMID 14752841 DOI: 10.1002/Hep.20031  0.373
2004 Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nature Reviews. Cancer. 4: 45-60. PMID 14681689 DOI: 10.1038/Nrc1251  0.649
2004 Suryanarayanan G, Keifer PA, Wang G, Kinarsky L, Hollingsworth MA, Sherman S. NMR-based structural studies of the glycosylated MUC1 tandem repeat peptide International Journal of Molecular Sciences. 5: 84-92. DOI: 10.3390/I5030084  0.757
2003 Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Research. 63: 5011-20. PMID 12941828  0.811
2003 Kinarsky L, Suryanarayanan G, Prakash O, Paulsen H, Clausen H, Hanisch FG, Hollingsworth MA, Sherman S. Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core. Glycobiology. 13: 929-39. PMID 12925576 DOI: 10.1093/Glycob/Cwg109  0.764
2003 Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. The Journal of Biological Chemistry. 278: 38029-39. PMID 12832415 DOI: 10.1074/Jbc.M304333200  0.572
2002 VanLith ML, Kohlgraf KG, Sivinski CL, Tempero RM, Hollingsworth MA. MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. International Immunology. 14: 873-82. PMID 12147624 DOI: 10.1093/Intimm/Dxf053  0.79
2002 Sivinski CL, Kohlgraf KG, VanLith ML, Morikane K, Tempero RM, Hollingsworth MA. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Cancer Immunology, Immunotherapy : Cii. 51: 327-40. PMID 12111121 DOI: 10.1007/S00262-002-0277-3  0.794
2002 Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, Wilentz RE, Hruban RH, Argani P. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. American Journal of Clinical Pathology. 117: 791-6. PMID 12090430 DOI: 10.1309/7Y7N-M1Wm-R0Yk-M2Va  0.345
2002 Shiraga T, Smith D, Nuthall HN, Hollingsworth MA, Harris A. Identification of two novel elements involved in human MUCI gene expression in vivo. Molecular Medicine (Cambridge, Mass.). 8: 33-41. PMID 11984004 DOI: 10.1007/Bf03402001  0.357
2002 Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. The American Journal of Pathology. 160: 1239-49. PMID 11943709 DOI: 10.1016/S0002-9440(10)62551-5  0.302
2002 Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, Kern SE. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Research. 62: 819-26. PMID 11830538  0.317
2002 Khorrami AM, Choudhury A, Andrianifahanana M, Varshney GC, Bhattacharyya SN, Hollingsworth MA, Kaufman B, Batra SK. Purification and characterization of a human pancreatic adenocarcinoma mucin. Journal of Biochemistry. 131: 21-9. PMID 11754731 DOI: 10.1093/Oxfordjournals.Jbchem.A003073  0.322
2001 Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Büchler MW, Aubert JP, Batra SK. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 4033-40. PMID 11751498  0.36
2001 McDermott KM, Crocker PR, Harris A, Burdick MD, Hinoda Y, Hayashi T, Imai K, Hollingsworth MA. Overexpression of MUC1 reconfigures the binding properties of tumor cells. International Journal of Cancer. 94: 783-91. PMID 11745478 DOI: 10.1002/Ijc.1554  0.77
2001 Silverman HS, Parry S, Sutton-Smith M, Burdick MD, McDermott K, Reid CJ, Batra SK, Morris HR, Hollingsworth MA, Dell A, Harris A. In vivo glycosylation of mucin tandem repeats. Glycobiology. 11: 459-71. PMID 11445551 DOI: 10.1093/Glycob/11.6.459  0.721
2001 Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A. Identification of MUC1 proteolytic cleavage sites in vivo Biochemical and Biophysical Research Communications. 283: 715-720. PMID 11341784 DOI: 10.1006/Bbrc.2001.4775  0.723
2001 Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. Invasion-specific genes in malignancy: Serial analysis of gene expression comparisons of primary and passaged cancers Cancer Research. 61: 1833-1838. PMID 11280733  0.311
2001 Morikane K, Tempero R, Sivinski CL, Kitajima S, Gendler SJ, Hollingsworth MA. Influence of organ site and tumor cell type on MUC1-specific tumor immunity. International Immunology. 13: 233-40. PMID 11157856 DOI: 10.1093/Intimm/13.2.233  0.817
2000 Kitamura N, Iwamura T, Taniguchi S, Yamanari H, Kawano K, Hollingsworth MA, Setoguchi T. High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice Clinical and Experimental Metastasis. 18: 561-571. PMID 11688961 DOI: 10.1023/A:1011900818419  0.36
2000 Kohsaki T, Nishimori I, Nakayama H, Miyazaki E, Enzan H, Nomoto M, Hollingsworth MA, Onishi S. Expression of UDP-GalNAc:Polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer Journal of Gastroenterology. 35: 840-848. PMID 11085493 DOI: 10.1007/S005350070021  0.417
2000 Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule International Journal of Cancer. 88: 507-518. PMID 11058865 DOI: 10.1002/1097-0215(20001115)88:4<507::Aid-Ijc1>3.0.Co;2-0  0.491
2000 Choudhury A, Moniaux N, Winpenny JP, Hollingsworth MA, Aubert JP, Batra SK. Human MUC4 mucin cDNA and its variants in pancreatic carcinoma Journal of Biochemistry. 128: 233-243. PMID 10920259 DOI: 10.1093/Oxfordjournals.Jbchem.A022746  0.393
2000 Akisawa N, Nishimori I, Iwamura T, Hollingsworth MA, Onishi S. Increased expression of ezrin is related with the metastatic potential of human pancreatic adenocarcinoma Gastroenterology. 118: A764. DOI: 10.1016/S0016-5085(00)85195-1  0.353
1999 Bennett EP, Hassan H, Mandel U, Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG, Olofsson S, Clausen H. Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. The Journal of Biological Chemistry. 274: 25362-70. PMID 10464263 DOI: 10.1074/Jbc.274.36.25362  0.301
1999 Beum PV, Singh J, Burdick M, Hollingsworth MA, Cheng PW. Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes. The Journal of Biological Chemistry. 274: 24641-8. PMID 10455130 DOI: 10.1074/Jbc.274.35.24641  0.475
1999 Hollingsworth MA. Proteins expressed by pancreatic duct cells and their relatives Annals of the New York Academy of Sciences. 880: 38-49. PMID 10415849 DOI: 10.1111/J.1749-6632.1999.Tb09508.X  0.402
1999 Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential Biochemical and Biophysical Research Communications. 258: 395-400. PMID 10329398 DOI: 10.1006/Bbrc.1999.0653  0.414
1999 Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression American Journal of Physiology - Gastrointestinal and Liver Physiology. 276: G941-G950. PMID 10198338 DOI: 10.1152/Ajpgi.1999.276.4.G941  0.317
1999 Reid CJ, Burdick MD, Hollingsworth MA, Harris A. CFTR expression does not influence glycosylation of an epitope-tagged MUC1 mucin in colon carcinoma cell lines. Glycobiology. 9: 389-98. PMID 10089213 DOI: 10.1093/Glycob/9.4.389  0.397
1999 Morikane K, Tempero RM, Sivinski CL, Nomoto M, Van Lith ML, Muto T, Hollingsworth MA. Organ-specific pancreatic tumor growth properties and tumor immunity. Cancer Immunology, Immunotherapy : Cii. 47: 287-96. PMID 10022473 DOI: 10.1007/S002620050533  0.824
1999 Schwientek T, Nomoto M, Levery SB, Merkx G, van Kessel AG, Bennett EP, Hollingsworth MA, Clausen H. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. The Journal of Biological Chemistry. 274: 4504-12. PMID 9988682 DOI: 10.1074/Jbc.274.8.4504  0.322
1999 Tempero RM, Rowse GJ, Gendler SJ, Hollingsworth MA. Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice International Journal of Cancer. 80: 595-599. PMID 9935162 DOI: 10.1002/(Sici)1097-0215(19990209)80:4<595::Aid-Ijc18>3.0.Co;2-B  0.427
1998 Mack DR, Cheng PW, Perini F, Wei S, Hollingsworth MA. Altered expression of sialylated carbohydrate antigens in HT29 colonic carcinoma cells. Glycoconjugate Journal. 15: 1155-63. PMID 10372971 DOI: 10.1023/A:1006924208135  0.301
1998 Tempero RM, VanLith ML, Morikane K, Rowse GJ, Gendler SJ, Hollingsworth MA. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 161: 5500-6. PMID 9820526  0.819
1998 Sharma P, Dudus L, Nielsen PA, Clausen H, Yankaskas JR, Hollingsworth MA, Engelhardt JF. MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands in human bronchial airways American Journal of Respiratory Cell and Molecular Biology. 19: 30-37. PMID 9651178 DOI: 10.1165/Ajrcmb.19.1.3054  0.329
1998 Göttke MU, Keller K, Belley A, Garcia RM, Hollingsworth MA, Mack DR, Chadee K. Functional heterogeneity of colonic adenocarcinoma mucins for inhibition of Entamoeba histolytica adherence to target cells. The Journal of Eukaryotic Microbiology. 45: 17S-23S. PMID 9561779 DOI: 10.1111/J.1550-7408.1998.Tb04519.X  0.374
1998 Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Research. 58: 315-21. PMID 9443411  0.825
1998 Morikane K, Tempero RM, Hollingsworth MA. A murine model for human pancreatic cancer: Orthotopic injection of syngeneic pancreatic tumor cells Gastroenterology. 114: A647. DOI: 10.1016/S0016-5085(98)82647-4  0.474
1998 Kohsaki T, Nishimori I, Miyaji E, Okamoto N, Akisawa Y, Tamura S, Morita M, Onishi S, Hollingsworth M. Expression of UDP-GalNAc: Polypeptide N-acetyl-galactos-aminyltransferase in human gastric cancer Gastroenterology. 114: A627. DOI: 10.1016/S0016-5085(98)82563-8  0.31
1998 VanLith ML, Tempero RM, Gendler SJ, Hollingsworth MA. In vitro kinetic analysis of cellular anti-MUC1 immune responses in MUC1 transgenic mice Faseb Journal. 12: A891.  0.806
1998 Tempero RM, Morikane K, Vanlith ML, Gendler SJ, Hollingsworth MA. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model Faseb Journal. 12: A891.  0.817
1997 Ikematsu Y, Liu G, Fienhold MA, Cano M, Adrian TE, Hollingsworth MA, Williamson JE, Sanger W, Tomioka T, Pour PM. In vitro pancreatic ductal cell carcinogenesis. International Journal of Cancer. Journal International Du Cancer. 72: 1095-103. PMID 9378545 DOI: 10.1002/(Sici)1097-0215(19970917)72:6<1095::Aid-Ijc26>3.0.Co;2-2  0.39
1997 Kolar C, Caffrey T, Hollingsworth M, Scheetz M, Sutherlin M, Weide L, Lawson T. Duct Epithelial Cells Cultured from Human Pancreas Processed for Transplantation Retain Differentiated Ductal Characteristics Pancreas. 15: 265-271. PMID 9336790 DOI: 10.1097/00006676-199710000-00008  0.331
1997 Burdick MD, Harris A, Reid CJ, Iwamura T, Hollingsworth MA. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines Journal of Biological Chemistry. 272: 24198-24202. PMID 9305871 DOI: 10.1074/Jbc.272.39.24198  0.476
1997 Iwamura T, Caffrey TC, Kitamura N, Yamanari H, Setoguchi T, Hollingsworth MA. P-selectin expression in a metastatic pancreatic tumor cell line (SUIT- 2) Cancer Research. 57: 1206-1212. PMID 9067294  0.378
1997 Yonezawa S, Sueyoshi K, Nomoto M, Kitamura H, Nagata K, Arimura Y, Tanaka S, Hollingsworth MA, Siddiki B, Kim YS, Sato E. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: Its close relationship with prognosis of the patients Human Pathology. 28: 344-352. PMID 9042800 DOI: 10.1016/S0046-8177(97)90134-9  0.403
1997 McKie AB, Iwamura T, Leung HY, Hollingsworth MA, Lemoine NR. Alu-polymerase chain reaction genomic fingerprinting technique identifies multiple genetic loci associated with pancreatic tumourigenesis Genes Chromosomes and Cancer. 18: 30-41. PMID 8993978 DOI: 10.1002/(Sici)1098-2264(199701)18:1<30::Aid-Gcc4>3.0.Co;2-2  0.305
1996 Smith AN, Barth ML, McDowell TL, Moulin DS, Nuthall HN, Hollingsworth MA, Harris A. A regulatory element in intron 1 of the cystic fibrosis transmembrane conductance regulator gene. The Journal of Biological Chemistry. 271: 9947-54. PMID 8626632 DOI: 10.1074/Jbc.271.17.9947  0.342
1995 Toshkov IA, Chaney WG, Colcher DM, Hollingsworth MA, Bratanova TK, Perini F, Pour PM. A novel adhesion factor produced by hamster pancreatic cancer cell line is effective on normal and carcinoma cell lines of different species. International Journal of Pancreatology : Official Journal of the International Association of Pancreatology. 18: 249-55. PMID 8708397 DOI: 10.1007/Bf02784949  0.392
1994 Hollingsworth MA, Strawhecker JM, Caffreyi TC, Mack DR. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mrnas in human pancreatic and intestinal tumor cell lines International Journal of Cancer. 57: 198-203. PMID 8157358 DOI: 10.1002/Ijc.2910570212  0.449
1994 Mack DR, Hollingsworth MA. Alteration in Expression of MUC2 and MUC3 mRNA Levels in HT29 Colonic Carcinoma Cells Biochemical and Biophysical Research Communications. 199: 1012-1018. PMID 8135773 DOI: 10.1006/Bbrc.1994.1330  0.305
1994 Longnecker DS, Pour PM, Scarpelli DG, Caldas C, Redston MS, Hahn SA, Seymour AB, Hruban RH, Yeo CJ, Kern SE, Ruggeri BA, Klein-Szanto AJP, Huang LY, Lang D, Andr’en-Sandberg Å, ... ... Hollingsworth MA, et al. Investigational strategies for detection and intervention in early-stage pancreatic cancer International Journal of Pancreatology. 16: 183-310. PMID 7868945 DOI: 10.1007/Bf02944330  0.312
1993 Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers Carcinogenesis. 14: 2575-2579. PMID 8269629 DOI: 10.1093/Carcin/14.12.2575  0.449
1992 Hollingsworth MA, Batra SK, Qi WN, Yankaskas JR. MUC1 mucin mRNA expression in cultured human nasal and bronchial epithelial cells American Journal of Respiratory Cell and Molecular Biology. 6: 516-520. PMID 1581075 DOI: 10.1165/Ajrcmb/6.5.516  0.327
1992 Batra SK, Metzgar RS, Worlock AJ, Hollingsworth MA. Expression of the human MUC1 mucin cDNA in a hamster pancreatic tumor cell line HP-1 International Journal of Pancreatology. 12: 271-283. PMID 1289420 DOI: 10.1007/Bf02924367  0.316
1991 Batra SK, Metzgar RS, Hollingsworth MA. A simple, effective method for the construction of subtracted cDNA libraries Genetic Analysis Techniques and Applications. 8: 129-133. PMID 1878262 DOI: 10.1016/1050-3862(91)90029-Q  0.38
1991 Batra SK, Kern HF, Worlock AJ, Metzgar RS, Hollingsworth MA. Transfection of the human Muc 1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: Integration, expression and ultrastructural changes Journal of Cell Science. 100: 841-849. PMID 1814933  0.309
1990 Lan MS, Hollingsworth MA, Metzgar RS. Polypeptide Core of a Human Pancreatic Tumor Mucin Antigen Cancer Research. 50: 2997-3001. PMID 2334903  0.303
1984 Hollingsworth MA, Evans DL. Helper factor(s) generated by tumor-immune rats for lymphoproliferative responses to syngeneic tumor cells Journal of the National Cancer Institute. 72: 1357-1363. PMID 6233443 DOI: 10.1093/Jnci/72.6.1357  0.579
1984 Hogan KT, Hollingsworth MA, Seymour RE, Quinn MK, Evans DL. Suppression of polyclonal, tumor cell and alloantigen-induced proliferation: Identification of cycloxygenase pathway dependent and independent mechanisms Immunopharmacology. 7: 49-57. PMID 6232242 DOI: 10.1016/0162-3109(84)90007-9  0.6
1983 Sterchi JM, Evans DL, Hollingsworth MA, Brown JJ, Mutton TP, Chung M. Evaluation of technique for autotransplantation of the spleen in dogs American Surgeon. 49: 625-631. PMID 6638704  0.492
1983 Hollingsworth MA, Evans DL. Changes in spleen cell proliferative responses and resistance to syngeneic tumor challenge in aging NBR rats Mechanisms of Ageing and Development. 22: 321-333. PMID 6226837 DOI: 10.1016/0047-6374(83)90086-6  0.539
1982 Hollingsworth MA, Evans DL. Differences in spleen suppressor cell content in rats with progressing and regressing tumors Journal of the National Cancer Institute. 69: 53-58. PMID 6212710  0.564
1981 Hollingsworth MA, Barrowclough J, Evans DL. Age-related increases in mitogenic responses and natural immunity to a syngeneic fibrosarcoma in rats Mechanisms of Ageing and Development. 17: 95-106. PMID 7311620 DOI: 10.1016/0047-6374(81)90129-9  0.559
Show low-probability matches.